Aldeyra Therapeutics Inc ALDX:NASDAQ

Last Price$2.46NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.18(6.82%)
Bid (Size)$2.45 (10)
Ask (Size)$2.67 (12)
Day Low / High$2.45 - 2.62
Volume629.7 K

View Biotechnology IndustryPeer Comparison as of 05/18/2022


Aldeyra Therapeutics Inc ( NASDAQ )

Price: $2.46
Change: -0.18 (6.82%)
Volume: 629.7 K
4:00PM ET 5/18/2022

Harvard Bioscience Inc ( NASDAQ )

Price: $3.65
Change: -0.09 (2.41%)
Volume: 166.6 K
4:00PM ET 5/18/2022

DarioHealth Corp ( NASDAQ )

Price: $6.45
Change: -0.74 (10.29%)
Volume: 439.9 K
4:00PM ET 5/18/2022

CorMedix Inc ( NASDAQ )

Price: $3.60
Change: -0.22 (5.76%)
Volume: 361.0 K
4:00PM ET 5/18/2022

Cymabay Therapeutics Inc ( NASDAQ )

Price: $1.90
Change: 0.00 (0.00%)
Volume: 666.9 K
4:00PM ET 5/18/2022

Read more news Recent News

-- Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Posts Q1 Loss $-0.29
7:09AM ET 5/05/2022 MT Newswires


Omega Therapeutics Hires Aldeyra Therapeutics Chief Financial Officer Joshua Reed for Same Role
7:49AM ET 4/29/2022 MT Newswires

Omega Therapeutics (OMGA) said Friday it appointed Joshua Reed as chief financial officer, effective May 23. Reed, who was most recently CFO of Aldeyra...

HC Wainwright Assumes Aldeyra Therapeutics at Buy with $15 Price Target
9:34AM ET 4/27/2022 MT Newswires

Aldeyra Therapeutics (ALDX) has an average rating of buy and price targets ranging from $10 to $30, according to analysts polled by Capital IQ. (MT...

Aldeyra Therapeutics Completes Enrolling Patients in Dry Eye Disease Late-Stage Trial
9:37AM ET 4/05/2022 MT Newswires

Aldeyra Therapeutics (ALDX) said Tuesday that it has finalized enrollment in the late-stage trial of 0.25% reproxalap ophthalmic solution in individuals...

Company Profile

Business DescriptionAldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA. View company web site for more details
Address131 Hartwell Avenue
Lexington, Massachusetts 02421
Number of Employees19
Recent SEC Filing05/18/20228-K
President, Chief Executive Officer & DirectorTodd C. Brady
Chief Financial Officer, Treasurer & VP-FinanceBruce Greenberg
Senior Vice President-Clinical DevelopmentJames A. Gow
Chief Development OfficerStephen G. Machatha

Company Highlights

Price Open$2.62
Previous Close$2.46
52 Week Range$2.36 - 13.18
Market Capitalization$143.4 M
Shares Outstanding58.3 M
SectorHealth Technology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.11
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-29.78%

Analyst Ratings as of 04/26/2022

Consensus RecommendationConsensus Icon
Powered by Factset